LCM
MLTX icon

Legato Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Legato Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,142
Closed -$240K – 593
2025
Q1 		$240K Buy
+6,142
New +$265K 0.03% 505

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Legato Capital Management's MLTX Position: Q2 2025 in Review

Legato Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q2 2025, closing a stake of 6,142 shares — an estimated $240K sold.

Legato Capital Management first reported a position in MLTX in Q1 2025 and held it in 1 quarter. The position peaked at $240K in Q1 2025. 130 funds tracked by Wall St. Rank hold MLTX as of Q2 2025.

  • Legato Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q2 2025 after selling out during the quarter.
  • Legato Capital Management sold 6,142 MoonLake Immunotherapeutics shares in Q2 2025, an estimated $240K.
  • Legato Capital Management first reported a position in MoonLake Immunotherapeutics in Q1 2025 and held it in 1 quarter.
  • Legato Capital Management's MoonLake Immunotherapeutics position peaked at $240K in Q1 2025.
  • 130 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2025.

Based on Legato Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.